Gidazepam, also known as hydazepam or hidazepam,[1] is a drug which is an atypical benzodiazepine derivative, developed in the Soviet Union.[2][3] It is a selectively anxiolytic benzodiazepine.[4] It also has therapeutic value in the management of certain cardiovascular disorders.[5][6][7][8][9]
Clinical data | |
---|---|
Trade names | Gidazepam IC |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | ~87 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C17H15BrN4O2 |
Molar mass | 387.2 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Gidazepam is a prodrug for its active metabolite 7-bromo-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one (desalkylgidazepam or bromo-nordazepam).[10][11] It is used as an antianxiety drug. Its anxiolytic effects can take several hours to manifest after dosing however, as it is the active metabolite which primarily gives the anxiolytic effects, and Gidazepam's half-life is among the longest of all benzodiazepines.[12]